SCHEMBL7530874

SCHEMBL7530874

CCOC(Cc1ccc(OCCCN2c3ccccc3C=Cc3ccccc32)cc1)C(=O)O

nearest known ligand 0.90

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.90
PPARG P37231 16/20 0.90
PPARD Q03181 7/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7533817 0.95 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL7529777 0.93 PPARA (0.78) PPARAPPARGPPARD
SCHEMBL7532648 0.90 PPARG (0.73) PPARAPPARGPPARD
SCHEMBL7530489 0.88 PPARA (0.80) PPARAPPARGPPARD
SCHEMBL7527048 0.88 PPARA (0.74) PPARAPPARGPPARD
SCHEMBL7527216 0.88 PPARA (0.86) PPARAPPARGPPARD
SCHEMBL7534045 0.86 PPARG (0.68) PPARAPPARGPPARD
SCHEMBL7531154 0.85 PPARG (0.83) PPARAPPARGPPARD
SCHEMBL7531092 0.85 PPARG (0.92) PPARAPPARGPPARD
SCHEMBL7532165 0.84 PPARG (0.81) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115657-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma JEPPESEN LONE (DK) 2002-08-22 US claimed
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-15 US claimed
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-01 US claimed
US-6468996-B1 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. NOVO NORDISK A/S (DK) 2002-10-22 US disclosed
US-20020115657-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma JEPPESEN LONE (DK) 2002-08-22 US disclosed
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-15 US disclosed
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885
US-20020115657-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.